Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis

Recruiting now · Not applicable

Conditions studied: Periodontal Disease

In brief

Periodontitis is a chronic, irreversible inflammatory disease affecting the supporting structures of the teeth. It is most commonly caused by bacteria in dental plaque, also known as biofilm. The disease typically begins as gingivitis, a reversible inflammation of the gums resulting from plaque accumulation. Without appropriate intervention-such as maintaining proper oral hygiene and removing plaque-gingivitis can progress to periodontitis, leading to the loss of clinical attachment, alveolar bone resorption, and eventually tooth loss. Early diagnosis and regular treatment of periodontal disease are essential to prevent disease progression. The treatment of periodontitis is primarily causal and involves the mechanical removal of plaque. Initial therapy is non-surgical, consisting of scaling and root planing, and may be followed by surgical procedures if required. In addition to mechanical cleaning, increasing attention has been given to adjunctive, non-invasive therapies such as mouth rinses or oral solutions containing chlorhexidine or hydrogen peroxide. These agents have antimicrobial properties, help reduce plaque accumulation, and support tissue healing. Hydrogen peroxide mouth rinses have been used for more than a century as an adjunct to mechanical plaque removal and for the prevention or management of oral infections. However, despite their long history of use, clinical studies evaluating hydrogen peroxide-based mouth rinses remain limited and heterogeneous in design, which makes it difficult to compare findings across studies. The objective of this post-marketing clinical study is to generate additional data on the safety and efficacy of a hydrogen peroxide mouth rinse as an adjunctive therapy in the treatment of periodontitis. The study will evaluate two hydrogen peroxide concentrations: a 1.5% solution (Oroxid® sensitive) and a 3% solution (Oroxid® forte).

Key facts

Study ID

NCT07257887

Run by

ENIKAM d.o.o.

People needed

90

Starts

2025-11-19

Expected to finish

2026-05-31

Last updated by the study team

2025-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Systemically healthy participants aged 18 years or older.
• Generalized periodontitis, Stage III, Grade B.
• Presence of three or more periodontal pockets deeper than 5 mm.
• At least 16 natural teeth (excluding wisdom teeth).
• Ability to comply with oral hygiene instructions following the intervention.
• Signed informed consent form after being fully informed about the study.

You may not qualify if…

• Periodontal treatment within the past six months.
• Dental procedures (surgery, professional cleaning, scaling and root planing, laser therapy, piezotome) within the past six months.
• Periodontitis, Stage IV.
• Use of mouth rinses or oral gels within the past month.
• Use of antibiotic therapy within the past three months.
• Ongoing therapy with antihypertensives, antilipemics, antiarrhythmics, or other cardiovascular medications.
• Systemic diseases such as diabetes, HIV/AIDS, liver diseases, chronic kidney disease, tuberculosis, and autoimmune disorders (e.g., lupus, scleroderma, Crohn's disease).
• History of cardiovascular diseases, including acute myocardial infarction, angina pectoris, heart failure, atrial fibrillation, atrioventricular block, peripheral artery disease, or stroke.
• Therapy with immunosuppressive agents.
• Allergy to any ingredients of the study products.
• Pregnant or breastfeeding women.

Where it is running

• Klinika Križaj Ljubljana — Ljubljana, Slovenia (enrolling)
• Ustna medicina d.o.o. — Ljubljana, Slovenia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.